A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

This study tests a new oral drug called TTYP01 in patients with early symptomatic Alzheimer's disease — specifically mild cognitive impairment (MCI) or mild Alzheimer's dementia — to see if it can improve or slow the decline in memory and thinking. Participants must have biological evidence of Alzheimer's confirmed through blood tests or brain scans. **You may be eligible if...** - You are between 60 and 85 years old - You have confirmed MCI due to Alzheimer's or mild Alzheimer's dementia - Your cognitive test scores are within a specified range (MMSE ≥22, CDR 0.5–1.0) - You have a positive blood test for a protein called p-tau 217 and/or a positive amyloid PET brain scan - You have a study partner (family member or caregiver) who can spend at least 8 hours per week with you - You have been experiencing gradual memory decline for at least 6 months **You may NOT be eligible if...** - You have had a brain infection or traumatic brain injury - You have severe heart disease, atrial fibrillation, or recent heart failure - You have another cause of cognitive impairment beyond Alzheimer's - You have a history of stroke or seizure in the past year - You have significant depression symptoms - You have active cancer (within the past 3 years, with some exceptions) - You have HIV, active syphilis, hepatitis B, or hepatitis C Talk to your doctor to see if this trial is right for you.